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Cerebral sinus thrombosis has been reported as an uncommon complication of ulcerative colitis (UC), occurring in up to 7.5%
of cases. It is suspected to be a consequence of genetic predisposition and the hypercoagulable state occurring during disease
relapse. We report a case of a 23-year-old male patient with one-year history of UC. He presented to the Emergency Room
with left-sided progressive hemiparesis, numbness, hemiparesthesia, and pain, which followed a recent exacerbation of UC. The
patient died 3 days after admission and an autopsy revealed superior and inferior sagittal sinus and cortical vein thrombosis
with associated cerebral edema, hemorrhagic infarction, and herniation. The gastrointestinal tract had continuous cobblestone
appearance extending from rectum to cecum, with hemorrhage and ulceration, consistent with active UC. Awareness of this rare
complication of UC can contribute to early recognition and attempts at treatment of this serious and often fatal condition.
1.Introduction
Inﬂammatory bowel disease (IBD) comprises two major
entities: ulcerative colitis (UC) and Crohn disease (CD).
Ulcerative colitis is an idiopathic chronic IBD that is a conse-
quence of complex interaction of environmental factors and
genetic susceptibility [1]. It often occurs in patients between
the ages of 20 and 30 years, with a second peak between the
agesof 70 and 80 years. UC can be regarded asa systemic dis-
ease, and extraintestinal complications have been described
in the skin, joints, bones, lungs, blood, eyes, kidneys, liver,
and peripheral and central nervous system. CNS mani-
festations are particularly severe: they include thrombotic
and cerebrovascular disease, myelopathy, cerebral vasculitis,
multiple sclerosis, and acute disseminated encephalomyelitis
[2]. Patients with IBD can also develop a hypercoagulable
state and have been noticed to have an increased risk of
various thrombotic events. These patients tend to suﬀer
thrombosis earlier in life than patients without IBD [3].
Deep venous thrombosis and pulmonary thromboembolism
are the two most common thrombotic complications of
UC [4]. Cerebral vein and sinus thrombosis (CVST) has
been reported as an uncommon but severe complication of
UC and CD, ranging in frequency from 1.3% up to 7.5%
of cases yearly depending on the clinical study [5]. The
exact pathogenesis of this complication remains unknown
and has been largely attributed to a hypercoagulable state
that can occur in these patients. The thrombosis occurs
more frequently during disease relapse but has also been
reported 10 years after colectomy for UC [6]. The outcome
is variable and may include either signiﬁcant neurological
deﬁcit or death when not appropriately treated. Due to its
nonspeciﬁc clinical presentation and low incidence, CVST
is not usually readily recognized and treatment may be
delayed, impacting on the prognosis. Neurology experts rec-
ommend prompt systemic anticoagulation, preferably with
low-molecularweightheparin,andmanagementoftheacute
complications of intracranial hypertension. Thrombolytics
may be considered for those patients with rapid neurologic
deterioration [7–19].
While most published cases associating CVST, UC, and
CD [3, 4, 6, 16, 18, 20–28]( Table 1) report good clinical2 Pathology Research International
Table 1: Inﬂammatory bowel disease cases complicated by cerebral thrombosis: treatment and outcomes as reported in the reviewed
literature.
Reference Age/Sex Inﬂammatory
bowel disease
Onset of symptoms
to diagnosis Initial Treatment Later Treatment Outcome
Prasad et al. [16] 5/F Crohn’s 3 days Venous sinus angioplasty
and local tPA
Systemic
anticoagulation Complete recovery
Philipsetal.[15] 35/F UC 4 day
Local Urokinase and
mechanical clot
maceration
Systemic
anticoagulation Complete recovery
Philipsetal.[15] 14/F IBD Unknown Local Urokinase Systemic
anticoagulation Complete recovery
Kao et al. [12] 14/F UC Unknown Local urokinase Systemic
anticoagulation
Partial resolution
of symptoms
Kao et al. [12] 7/F UC Unknown LMWH ASA Partial resolution
of symptoms
Kao et al. [12] 20/F UC Unknown LMWH Systemic
anticoagulation Complete recovery
Kao et al. [12] 13/F UC Unknown LMWH Systemic
anticoagulation Complete recovery
Wasay et al. [19] 23/F UC Unknown Local Urokinase Systemic
anticoagulation
Partial resolution
of symptoms
Wasay et al. [19] 34/F UC Unknown Local Urokinase Systemic
anticoagulation Complete recovery
Wasay et al. [19] 29/M UC Unknown Local Urokinase Systemic
anticoagulation
Partial resolution
of symptoms
Derdeyn and
Powers [20]
26/F UC 10 Warfarin Systemic
anticoagulation
Partial resolution
of symptoms
Murata et al.
[21]
19/M UC Unknown Heparin Unknown Complete recovery
Samal et al. [22] 20/M Crohn’s 3 Oral anticoagulants Unknown Partial resolution
of symptoms
Maag and
Prayson [3]
30/M Crohn’s 1 Recanalization attempt None Death
Tsujikawa et al.
[23]
27/M UC 9 Heparin and Urokinase Systemic
anticoagulation Complete recovery
Srivastava et al.
[24]
29/M UC 10 LMWH Systemic
anticoagulation Complete recovery
Wartenberg and
Palestrant [18]
43/F UC 4 Local thrombolysis
(rTPA)
Systemic
anticoagulation
Partial resolution
of symptoms
outcomes, that is not always the case. We report the case of
a 23-year-old Caucasian male with UC who succumbed to
a massive superior and inferior sagittal sinus and cerebral
corticalveinthrombosisfollowedbyalargeandfatalcerebral
hemorrhagic infarct, which occurred in the setting of UC
exacerbation.
2. Case History
The patient was a 23-year-old Caucasian male with one-year
history of UC. His disease was controlled until two weeks
prior to hospital admission, when he presented with bloody
diarrhea and abdominal pain. At that time he was placed on
prednisone 20mg, mesalamine 400mg TID, promethazine
12.5mgprn, metronidazol 500mg TID, and omeprazole
20mg for the UC relapse. He developed a worsening “band
like” dull headaches and neck pain but did not seek medical
attention until a week later, when he came to the Emergency
Room.Atthetimeofpresentation,heshowedprogressiveleft
sided hemiparesis accompanied by numbness, paresthesis,
and severe pain; he was admitted for further evaluation.
He denied fevers, photophobia, visual changes, dysarthria,
or dysphagia. Neurological examination revealed left-sided
hyperesthesia, hemiplegia, clonus, and a positive Babinski
sign. Pertinent laboratory ﬁndings included prolonged pro-
thrombine time (PT) of 17.8 seconds (reference range: 12.0–
14.7 seconds), with an INR at 1.5, and a normal PTT at
29.0 seconds (reference range: 22.8–33.5 seconds). White
bloodcellcountwasslightlyelevatedat10.3K/cmm(normal
3.5–10) with 80% neutrophils. Mild microcytic anemia was
present. A spinal tap was performed and the cerebrospinal
ﬂuid showed red blood cells, high glucose of 113mg/dl
(normal: 40–70), and high protein of 259mg/dl (normal 15–
45). Liver function tests were within normal limits. Urine
drug screen was negative for benzodiazepines, marihuana,
cocaine, opiates, amphetamines, and barbiturates. SerumPathology Research International 3
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Figure 1: (a) MRI angiogram showing patent cerebral arteries. ((b), (c), (d)) Sagittal and transverse MRI views, T1 and T2 weighed, depict
a large right hemorrhagic lesion with prominent edema and midline shift.
Toxoplasma titers were negative. Abnormal electrolytes
included chloride 99mmol/L (normal 100–111), potassium
2.8mmol/L (normal 3.5–5), and calcium 8.1mg/dl (normal
8.9–10.3). Albumin was low at 2.4g/dl (normal 3.5–5). D-
dimer and other laboratory markers of ﬁbrinolysis were not
ordered at the time. Since they would be positive in several
conditions such as hemorrhage, thrombosis, disseminated
intravascular coagulation, malignancy, liver failure, and
tissue trauma, these tests would not help in diﬀerentiating
between these possibilities.
At the time of admission, CT and MRI images of
the head were obtained (Figure 1). They showed rapidly
progressive cortical and subcortical hemorrhages in the
right frontal and parietal lobes with surrounding edema
measuring up to 15cm and midline shift, as well as
unilateral enlargement of the left temporal region indicating
impending uncal herniation. An MRI angiography of the
h e a ds h o w e dn o r m a lc e r e b r a la r t e r i e sw i t hm a s se ﬀect upon
the right cerebral artery. A dedicated MRI venography was
not performed. The diﬀerential diagnosis based on clinical
and radiological ﬁndings included necrotizing vasculitis, an
infectious process with secondary hemorrhage and throm-
bosis (such as toxoplasmosis, neurocysticercosis, and herpes
encephalitis), cerebritis, primary and metastatic neoplastic
processes, and cerebral venous thrombosis. The possibility
of venous infarction or superior sagittal sinus thrombosis
was considered, but the presentation was thought to be
atypical given its unilaterality and the rapid progression of
the lesion on imaging. Thrombosis was more strongly felt to
be secondary to a primary infectious or vasculitic process.
Treatment with steroids was instituted to decrease the mass
eﬀect and treat the most likely diagnosis, which was CNS
vasculitis. Vancomicin, ceftriaxone, gancyclovir, acyclovir,
and pyrimethamine were also started given the possibility
of a bacterial, viral, or parasitic infectious etiology. No
anticoagulation was administered due to the hemorrhagic
nature of the lesion on imaging studies.
His clinical condition continued to worsen and mental
status further deteriorated with development of additional
neurological symptoms including hemianesthesia, slurred
speech, anisocoria, and lethargy. The patient was transferred
to the intensive care unit and was treated for increased
intracranialpressure;therapeuticmeasuresincludedinduced
hypocapnia, forced diuresis with IV-manitol, and placement
of a ventriculostomy catheter. However, despite aggressive
therapeutic measures the patient died within two days
following admission. A complete autopsy was performed.
At autopsy, the gross examination of the gastrointestinal
tract revealed continuous cobblestone appearance of the
mucosa extending from the rectum up to the cecum, with
areas of hemorrhage and ulceration (Figure 2). Microscopic
examination revealed characteristic ﬁndings of UC, includ-
ing chronic active colitis with crypt abscesses and inﬂamma-
tory pseudopolyps. There were in addition multiple thrombi
in the stomach, colon, liver, spleen, testis, and lung. CNS
examination revealed superior and inferior sagittal sinus4 Pathology Research International
Figure 2: Gross photograph of the large bowel segment examined
at autopsy. There is continuous cobblestone appearance of the
mucosa, due to presence of multiple ulcerations and inﬂammatory
pseudopolyps, a consequence of active ulcerative colitis.
Figure 3: Gross photograph of dura and thrombosed superior
sagittal sinus.
and cortical vein thrombosis (Figure 3), a right medial
frontoparietal hemorrhagic infarct with cerebral edema
(Figure 4),rightcingulate,bilateraluncalandrightcerebellar
tonsillar herniation and Duret hemorrhages. Histological
examination of the sections did not reveal any old infarcts
or previous CNS pathology. Brain tissue was submitted for
routine, acid fast, fungal, and viral cultures; all cultures were
negative.
3. Discussion
We report a case of a 23-year-old male with one-year history
of UC that developed superior and inferior cerebral sinus
thrombosis following disease relapse. Despite aggressive
therapy, the patient died two days following admission, an
unusually rapid fatal outcome when compared to the other
cases reported in the literature.
Thrombosis of the cerebral veins and sinuses usually
aﬀects young adults in their third decade of life with
an annual incidence of 3 cases per 1 million population,
although this varies widely depending on the study [2,
18, 29]. It also aﬀects children, especially neonates with
an incidence of 0.67 per 100,000 cases per year [30]. It
accounts for less than 1% of all strokes [9]. Eighty-ﬁve
percent of the patients show either an acquired or inherited
prothrombotic risk factors at the time of presentation.
A precipitating factor, such as reactivation of a chronic
disease, can often be identiﬁed. The usual culprits include
cancer, head trauma, drugs (especially oral contraceptives),
hematologic diseases that result in hyperviscosity, systemic
Figure 4: Gross photograph of brain showing right medial fronto-
parietal hemorrhage and edema.
inﬂammatory diseases, systemic infections (especially sepsis)
or infection involving the central nervous system, sinuses or
ear, genetic susceptibility such as protein C and S deﬁciency
and antithrombin deﬁciency, and other prothrombotic states
such as pregnancy [1]. Our patient developed thrombosis
of the cerebral veins in association with relapse of UC. A
thorough personal and family medical history did not reveal
any other prothrombotic risk factors, or a bleeding diathesis.
The etiology of hypercoagulationand thromboembolism
in IBD remains poorly understood. Coagulation factor
abnormalities such as elevated ﬁbrinogen level, factor V,
factor VIII, increase in circulating thrombin-antithrombin
complexes, and decreased antithrombin III have been
described;thrombocytosisandincreasedplateletaggregation
have also been documented [3, 31, 32]. However, there
is no substantial evidence to correlate hematological and
coagulation abnormalities with cerebral sinus thrombosis. In
ourcase,theonlycoagulationabnormalitydetectedincluded
prolonged PT, while aPTT, INR, and platelet count were
normal. Whether other coagulation factors were abnormal
and played a role in pathogenesis remains unknown.
A high level of suspicion of CVST is necessary in any
patient with recent unusual headache, stroke like symptoms,
seizures, or any other brain syndrome, due to its highly vari-
able presentation. That suspicion should be even stronger
in a young adult with neurological signs in the absence of
the usual cerebrovascular risk factors, such as hypertension,
diabetes, hyperlipidemia, smoking history, and prior history
of cardio or cerebrovascular events. The most frequent
sign at presentation is headache, which gradually increases
over a period of days, although it can also present as
an abrupt severe headache which can mimic subarachnoid
hemorrhage [1]. Our patient did present with what he
described as a band-like headache for a week before seekingPathology Research International 5
medical attention. Seizures are very common, occurring in
40 percent of the cases; however they were not present in
this case. Bilateral neurologic signs are the most common
presentation, and they usually follow a sudden onset. While
focal unilateral neurological symptoms such as aphasia
or hemiparesis are less common, they were among early
symptomsinourcase.Symptomsfromtheotherhemisphere
usually follow after a few days. Thrombosis of the cerebral
deep venous systems may present with other nonspeciﬁc
signs, such as delirium, mutism, behavioral problems, or
amnesia. When large lesions go unnoticed and therefore
treatmentisnotinstituted,cerebralherniationanddeathcan
occur. The delay from the onset of symptoms to diagnosis
averages 7 days [33]. The most frequently involved vessels
are transverse sinus (86%), superior sagittal sinus (62%),
straight sinus (18%), cortical veins (17%), vein of Galen,
and internal cerebral veins (11%) [1]. It is important to
note that this particular patient had symptoms for at least
a week before consulting a physician, which might have
added to the unusual presentation of unilateral symptoms,
leading to delay in diagnosis. Once CT and MRI images
of the CNS were obtained, the hemorrhagic lesion was
already too large, which led to a long list of diﬀerential
diagnoses.
Once cerebral vein thrombosis is clinically suspected, an
MRI and a magnetic resonance angiography (MRA) should
be ordered, which will show an abnormal signal both in T1-
and in T2-weighted images in a sinus or vein and absence of
ﬂow, respectively. CT is also helpful in ruling out other acute
cerebral disorders and should be the ﬁrst study ordered in
an emergency setting. MRI and MRA are considered the best
tools for diagnosis and follow-up [9].
Treatment of this disorder includes appropriate measures
to prevent or reverse cerebral herniation and stabilize the
patient. So far, acute management relies on treatment of
acute intracranial hypertension. Corticosteroids are usually
considered as a supplement to acetazolamide in patients
who present with severe papilledema and are administered
with the goal of reducing the systemic inﬂammatory state
associated with UC relapse. Placement of a cerebrospinal
ﬂuid draining catheter may be necessary if medical manage-
ment of intracranial hypertension is not helpful. All of these
measures were taken in this case, but regrettably the rapid
progression of the edema and herniation led to the patient’s
demise.
Several treatment modalities using diﬀerent anticoagula-
tion approaches have been evaluated, and studies and single-
case reports on this subject are available for review (Table 1).
Anticoagulant therapy is recommended to promote sponta-
neousthrombusresolution,circumventthrombusextension,
and prevent thromboembolism [9]. Most specialists now
agree to institute treatment with heparins as soon as the
diagnosis is conﬁrmed by MRI or other imaging techniques,
even in the presence of a hemorrhagic infarct [7, 9, 12, 17,
30]. One major concern with heparin treatment is the risk
of hemorrhage in patients with ischemic infarcts. In the
case we present, the extent of the hemorrhage was of such
magnitude that neurologists and neurosurgeons decided
to withhold the anticoagulant treatment since the risks
of further bleeding into the CNS outweighed the possible
beneﬁts. The treatment was therefore based on measures to
reduce the intracranial pressure.
For patients with ischemic infarcts due to cerebral
vein thrombosis, a study comparing low-molecular-weight
heparin (LMWH) and placebo for 3 weeks concluded
that there was no signiﬁcant increased risk of hemorrhage
with heparin [8]. In addition, treatment with subcutaneous
LMWH caused less major bleeding than intravenous heparin
and decreased the risk of pulmonary emboli [34]. Oral
anticoagulation should follow heparin treatment for at least
6 months, with a target INR of 2.5. Additional studies
are needed to deﬁne the most eﬀective treatment for this
condition.
In summary, our patient presented with symptoms a
week before seeking medical attention which led to a marked
delay in his diagnosis and hence treatment. The unilateral
presentation made the accurate suspicion for the diagnosis
more diﬃcult. The rapid progression of intracranial hemor-
rhage and hemorrhagic nature of the lesion precluded the
use of anticoagulant therapy even though CVST was in the
diﬀerentialdiagnosisandledtotheﬁnalfataloutcomewithin
two days of admission.
4. Conclusions
Cerebral sinus and vein thrombosis is a serious and often
fatal complication of idiopathic inﬂammatory bowel disease
if undiagnosed. It should be considered in any patient with
little or no known vascular risk factors presenting with a
severe headache and other focal or diﬀu s en e u r o l o gi c a ls i gn s .
Appropriate clinical information, prompt neuroimaging,
early diagnosis, and treatment are essential steps in avoiding
potentially fatal outcome. It is our goal to raise the awareness
and the index of suspicion among health professionals about
this entity, as quicker diagnosis and prompt management of
this complication are the only hopes to avoid fatal outcome.
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